FDA greenlights Benlysta autoinjector for pediatric patients with SLE

Global biopharma company GSK reports that the FDA has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab), a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody, for patients ≥5 years old with active systemic lupus erythematosus (SLE) who are receiving standard therapy. This option allows pediatric patients the possibility to receive the treatment at home. Previously, such children could only receive belimumab through an IV formulation, administered by healthcare professionals in a hospital or clinic setting.